International Cancer Conference Journal

, Volume 7, Issue 4, pp 152–155 | Cite as

Locally advanced pancreatic cancer successfully treated with high-dose helical tomotherapy

  • Yukihiro Hama
Case report


Complete surgical resection is the potentially curative treatment for pancreatic cancer, but only fewer than 20% of those individuals will be found to be eligible for surgery. Here we report a 49-year-old man with locally advanced pancreatic cancer successfully treated with high-dose radiotherapy using helical tomotherapy (66 Gy/33 fractions, 2 Gy per day over 6.5 weeks). To our knowledge, this is the first reported case of locally advanced pancreatic cancer curatively treated with helical tomotherapy alone.


Pancreatic neoplasms Radiation Radiotherapy, image-guided 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.


  1. 1.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013 CA. Cancer J Clin 63:11–30CrossRefGoogle Scholar
  2. 2.
    Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165:68–72CrossRefPubMedGoogle Scholar
  3. 3.
    Ji JS, Han CW, Jang JW et al (2010) Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer. Radiat Oncol 5:60. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Callery MP, Chang KJ, Fishman EK et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733CrossRefPubMedGoogle Scholar
  5. 5.
    Zschaeck S, Blumke B, Wust P et al (2017) Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS One 12:e0186341CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Crane CH (2016) Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer. J Radiat Res 57(Suppl 1):i53–i57CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    de Geus SWL, Eskander MF, Kasumova GG et al (2017) Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer 123:4158–4167CrossRefPubMedGoogle Scholar
  8. 8.
    Taylor R, Opfermann K, Jones BD et al (2012) Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical tomotherapy. J Med Imaging Radiat Oncol 56:332–337CrossRefPubMedGoogle Scholar
  9. 9.
    Chang JS, Wang ML, Koom WS et al (2012) High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 83:1448–1454CrossRefPubMedGoogle Scholar
  10. 10.
    Neoptolemos JP, Stocken DD, Dunn JA et al (2001) European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758–768CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024CrossRefGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2018

Authors and Affiliations

  1. 1.Department of Radiology, Tokyo-Edogawa Cancer CenterEdogawa HospitalTokyoJapan

Personalised recommendations